The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Role of AI in determining treatment options and managing patients with resectable PDAC
Nelson Dusetti, PhD, Cancer Research Centre of Marseille, Marseille, France, discusses the potential role artificial intelligence (AI) could have in determining treatment options and managing patients with resectable pancreatic ductal adenocarcinoma (PDAC). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Predicting Med
Patents, Royalties, Other Intellectual Property – PCT/EP2022/065222. Simple transcriptomic signatures to determine chemosensitivity for pancreatic ductal adenocarcinoma. SATT Sud-Est. Inventors: N. Dusetti, N. Fraunhoffer, J. Iovanna, 2021. Licensing to Predicting Med.
